Cervical cancer clinical trials

Seattle Cancer Care Alliance (SCCA) was formed, in part, to bring promising new treatments to patients faster. For cervical cancer patients, this means more treatment options at SCCA than you might find elsewhere, including the chance to participate in one of many ongoing clinical trials conducted at SCCA and its partner organizations, Fred Hutch and UW Medicine.

Below is a list of cervical cancer clinical trials that are currently open and accepting patients at SCCA.
For general information about clinical trials, see the Patient Guide to Clinical Trials.

Displaying 10 of 10 trials

Start new search

A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes (LODESTAR)

LODESTAR: A Phase 2 MuLticenter, Open-label Study of Rucaparib as Treatment for SoliD Tumors Associated with DEleteriouS MuTations in Homologous RecombinAtion Repair Genes

Study ID:

NCT04171700

View Trial

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors

Investigator:

Kaylyn Kit Man Wong, MD

Study ID:

NCT03767348

View Trial

A Study to Evaluate the Safety, Tolerability of DN1508052-01 to Advanced Solid Tumors

A Phase I, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of DN1508052-01 as a Single Agent when Administered Subcutaneously to Adult Patients with Advanced Solid Tumors

Investigator:

Kaylyn Kit Man Wong, MD

Study ID:

NCT03934359

View Trial

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3)

A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects with Selected Advanced Solid Tumors (DUET-3)

Investigator:

Jennifer M. Specht, MD

Study ID:

NCT03752398

View Trial

TR1801-ADC in Patients With Tumors That Express c-Met

A Phase 1, open label, first-in-human study of TR1801-ADC, an antibody drug conjugate (ADC), in patients with select solid tumors expressing c-Met

Investigator:

Kaylyn Kit Man Wong, MD

Study ID:

NCT03859752

View Trial

A Phase 1, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation.

A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors with a Specific KRAS Mutation

Investigator:

Andrew Coveler, MD

Study ID:

NCT03600883

View Trial

A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

A PHASE IA/IB OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF RO7198457 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS

Investigator:

Kaylyn Kit Man Wong, MD

Study ID:

NCT03289962

View Trial

Phase 1 Study of the Highly-selective RET Inhibitor BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-small Cell Lung Cancer (NSCLC) and other Advanced Solid Tumors

Investigator:

Christina S. Baik, MD, MPH

Study ID:

NCT03037385

View Trial

HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions

HPV Vaccine to Interrupt Progression of Vulvar and Anal Neoplasia (VIVA) Clinical Trial: A Randomized, Double-Blind, Placebo-Controlled Trial

Investigator:

Anna Wald, MD

Study ID:

NCT03051516

View Trial